Evaluation of ThoraQuik: a new device for the treatment of pneumothorax and pleural effusion

Abstract

Background: ThoraQuik is a device with a unique design incorporating an aspiration port and one-way valve controlled by a three-way tap, fit for purpose for the treatment of pneumothorax and pleural effusion. Its use, safety and efficacy were evaluated in a prospective observational trial.

Methods: Stage 1: The safety and ability of the device to penetrate the chest wall and the ease of use were evaluated in patients undergoing thoracoscopic procedures by introducing the device at a second port site under vision. Stage 2: The device was evaluated on patients with pneumothorax and pleural effusion. Clinical and radiological improvement were endpoints and operator feedback was evaluated.

Results: Phase 1: 10 patients (mean age: 48.5 years (18-76 years) six men) were studied between May 2005 and March 2007. Satisfactory penetration of the chest wall and safe entry in the pleural space was achieved. Phase 2: 20 patients (mean age: 59 years (24-81 years) 13 men) were recruited between May 2007 and May 2008. 10 patients presented with pneumothorax (tension pneumothorax, n=1) and 10 had pleural effusions. One patient withdrew consent and another patient was withdrawn as there was no fluid on trial aspiration. Of the 18 who completed the study, 10/18 had partial and 7/18 patients had complete resolution with no change in one. The qualitative assessments of the ThoraQuik in terms of ease of use and utility were positive.

Conclusions: ThoraQuik achieves satisfactory penetration of the chest wall. It was safe and easy to use to manage pneumothoraces and pleural effusions.